Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Super-Selective Intra-Arterial Administration of Verapamil for Neuroprotection After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Phase I Study

NCT02235558 is registered in ClinicalTrials.gov with Justin Fraser as lead sponsor.

NCT NCT02235558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02235558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Super-Selective Intra-Arterial Administration of Verapamil for Neuroprotection After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Phase I Study
Lead sponsor
Justin Fraser
Phase
Phase 1
Overall status
Completed
Start date
February 1, 2013
Completion date
March 21, 2016
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke